Elsevier established a free COVID-19 resource center in January 2020, offering English and Mandarin information on the virus. The center allows free access to research in PubMed Central and other repositories for unrestricted use. The article discusses the development of SARS-CoV-2 vaccines, highlighting the challenges and current status of vaccine research. SARS-CoV-2, the virus causing COVID-19, emerged in late 2019 and has infected over 870,000 people globally, with over 43,000 deaths. The virus is a betacoronavirus related to SARS and MERS, and it uses ACE2 as a receptor. Vaccines are crucial for reducing morbidity and mortality, but development is complex due to the virus's rapid emergence and the lack of existing vaccines. Current vaccine candidates include mRNA-based, recombinant protein-based, and viral-vector-based vaccines. Clinical trials are ongoing, with some showing promise. However, vaccine development is time-consuming, and it may take months or years to produce a safe and effective vaccine. The article also discusses the challenges of vaccine production, distribution, and the need for global collaboration. Despite the challenges, vaccines are essential for controlling the pandemic and preventing future outbreaks.Elsevier established a free COVID-19 resource center in January 2020, offering English and Mandarin information on the virus. The center allows free access to research in PubMed Central and other repositories for unrestricted use. The article discusses the development of SARS-CoV-2 vaccines, highlighting the challenges and current status of vaccine research. SARS-CoV-2, the virus causing COVID-19, emerged in late 2019 and has infected over 870,000 people globally, with over 43,000 deaths. The virus is a betacoronavirus related to SARS and MERS, and it uses ACE2 as a receptor. Vaccines are crucial for reducing morbidity and mortality, but development is complex due to the virus's rapid emergence and the lack of existing vaccines. Current vaccine candidates include mRNA-based, recombinant protein-based, and viral-vector-based vaccines. Clinical trials are ongoing, with some showing promise. However, vaccine development is time-consuming, and it may take months or years to produce a safe and effective vaccine. The article also discusses the challenges of vaccine production, distribution, and the need for global collaboration. Despite the challenges, vaccines are essential for controlling the pandemic and preventing future outbreaks.